The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
October 12, 2026
View Complete Issue         Table of Contents 2019 
Vusolimogene Oderparepvec (Tudriqev) – An Oncolytic Viral Therapy for Melanoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vusolimogene Oderparepvec (Tudriqev) – An Oncolytic Viral Therapy for Melanoma (online only)
October 12, 2026 (Issue: 1765)
Vusolimogene oderparepvec (Tudriqev – Replimune), a genetically-modified herpes simplex virus type 1 (HSV-1) oncolytic therapy, has been granted accelerated approval by the FDA for use in combination with the programmed death receptor-1...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Vusolimogene Oderparepvec (Tudriqev) – An Oncolytic Viral Therapy for Melanoma (online only)
Article code: 1765e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.